Turning Biological Complexity
into Precise Decision
Human-Relevant Models. Actionable Insights. Better Decisions.
We combine proprietary TME-Chip technology with deep expertise in oncology drug development, translational research, biomarker strategy, and multi-omics integration.
We partner with biopharmaceutical companies, academic medical centers, translational research laboratories, and clinical investigators to generate biologically relevant data and actionable insights that support drug development and precision oncology programs.
OUR SERVICES
Service Workflow
From Your Question to Actionable Development Insights
We work closely with you from understanding your scientific question,
designing the right study, and translating complex biological data into insights
that support better oncology drug development or treatment decisions.
We first work with you to understand your scientific question, therapeutic candidate, target indication, and development goals, then design a customized TME-Chip study with appropriate models, controls, treatment conditions, and readouts.
Clinically relevant biological samples and investigational therapies are prepared for testing, including small molecules, antibodies, ADCs, immunotherapies, or combination treatments.
Recreate key interactions between tumor, stromal, and immune cells within a dynamic microenvironment that more closely reflects human biology.
Monitor treatment response through live imaging, cellular activity, secreted biomarkers, and quantitative phenotypic measurements.
Characterize molecular changes associated with drug response, resistance mechanisms, and disease biology.
Combine phenotypic and molecular datasets to uncover biological drivers, predictive biomarkers, and translational insights.
Transform complex data into evidence-based recommendations that support smarter development decisions and precision oncology strategies.
Contact Us
Connect with Pythia Biotech to learn more about our products and services,
explore partnering opportunities, or discuss potential collaborations.
